StocksFundsScreenerSectorsWatchlists
XENE

XENE - Xenon Pharmaceuticals Inc Stock Price, Fair Value and News

41.27USD-1.70 (-3.96%)Market Closed

Market Summary

XENE
USD41.27-1.70
Market Closed
-3.96%

XENE Alerts

  • 2 major insider sales recently.

XENE Stock Price

View Fullscreen

XENE RSI Chart

XENE Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-17.07

Price/Sales (Trailing)

376.84

EV/EBITDA

-16.55

Price/Free Cashflow

-20.62

XENE Price/Sales (Trailing)

XENE Profitability

EBT Margin

-1936.45%

Return on Equity

-19.66%

Return on Assets

-18.9%

Free Cashflow Yield

-4.85%

XENE Fundamentals

XENE Revenue

Revenue (TTM)

9.4M

XENE Earnings

Earnings (TTM)

-182.4M

Earnings Growth (Yr)

-19.65%

Earnings Growth (Qtr)

7.67%

Breaking Down XENE Revenue

Last 7 days

-2.3%

Last 30 days

-8.5%

Last 90 days

-8.5%

Trailing 12 Months

13.8%

How does XENE drawdown profile look like?

XENE Financial Health

Current Ratio

23.65

Debt/Equity

0.01

Debt/Cashflow

-13.35

XENE Investor Care

Shares Dilution (1Y)

19.66%

Diluted EPS (TTM)

-2.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202222.8M21.2M13.2M9.4M
202129.4M18.3M19.9M18.4M
202013.9M27.3M30.3M32.2M
2019004.2M7.1M
2017001.5M1.1M
201612.2M8.5M4.7M1.8M
201527.4M26.1M17.2M15.6M
201427.0M26.7M29.1M28.4M
201317.6M20.8M24.1M27.4M
201200014.3M

Tracking the Latest Insider Buys and Sells of Xenon Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 08, 2024
garofalo elizabeth a.
sold
-95,583
45.69
-2,092
-
Mar 08, 2024
garofalo elizabeth a.
acquired
64,960
18.56
3,500
-
Mar 08, 2024
garofalo elizabeth a.
sold (taxes)
-64,993
46.16
-1,408
-
Mar 07, 2024
robin sherrington
sold (taxes)
-69,123
45.96
-1,504
evp, strategy & innovation
Mar 07, 2024
robin sherrington
acquired
85,113
9.85
8,641
evp, strategy & innovation
Mar 07, 2024
gannon steven
sold
-601,615
46.2781
-13,000
-
Mar 07, 2024
robin sherrington
sold
-330,290
46.2786
-7,137
evp, strategy & innovation
Dec 29, 2023
robin sherrington
sold
-
-
-8,398
evp, strategy & innovation
Dec 19, 2023
azab mohammad
acquired
42,552
9.85
4,320
-
Dec 14, 2023
patou gary
sold
-311,898
41.05
-7,598
-

1–10 of 50

Which funds bought or sold XENE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 11, 2024
17 CAPITAL PARTNERS, LLC
new
-
391,693
391,693
0.29%
Apr 11, 2024
SANDERS MORRIS HARRIS LLC
unchanged
-
-101,480
925,575
0.17%
Apr 10, 2024
CVA Family Office, LLC
added
60.61
762
2,282
-%
Apr 05, 2024
GAMMA Investing LLC
added
59.09
512
1,507
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
new
-
91,198
91,198
-%
Mar 19, 2024
Accent Capital Management, LLC
new
-
18,424
18,424
0.01%
Mar 11, 2024
VANGUARD GROUP INC
added
21.24
5,785,400
14,900,200
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
194
25,941,600
34,664,900
-%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
added
78.26
29,606,700
50,700,500
1.13%
Feb 20, 2024
Quarry LP
reduced
-77.78
-107,660
46,060
0.01%

1–10 of 43

Are Funds Buying or Selling XENE?

Are funds buying XENE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own XENE
No. of Funds

Unveiling Xenon Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
driehaus capital management llc
5.88%
4,345,180
SC 13G/A
Feb 14, 2024
avoro capital advisors llc
7.7%
5,666,666
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 08, 2024
wellington management group llp
5.56%
4,162,654
SC 13G
Feb 14, 2023
biotechnology value fund l p
1.1%
681,278
SC 13G/A
Feb 14, 2023
avoro capital advisors llc
7.8%
4,900,000
SC 13G/A
Feb 14, 2023
point72 asset management, l.p.
1.9%
1,178,324
SC 13G/A
Feb 10, 2023
driehaus capital management llc
7.49%
4,681,797
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 14, 2022
point72 asset management, l.p.
5.8%
2,992,597
SC 13G/A

Recent SEC filings of Xenon Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Mar 12, 2024
4
Insider Trading
Mar 12, 2024
4
Insider Trading
Mar 12, 2024
4
Insider Trading
Mar 12, 2024
4
Insider Trading
Mar 12, 2024
4
Insider Trading
Mar 12, 2024
4
Insider Trading
Mar 12, 2024
4
Insider Trading
Mar 11, 2024
4
Insider Trading
Mar 08, 2024
4
Insider Trading
Mar 08, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Xenon Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.2B
6.8B
-1.24% -34.47%
-8.53
5.87
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.7B
1.8B
0.05% -28.38%
-42.48
10.23
76.23% 61.08%
17.4B
2.4B
8.82% -6.19%
103.82
7.19
15.42% 18.43%
12.1B
3.7B
-8.57% -28.49%
20.24
3.27
8.87% 75.42%
MID-CAP
6.2B
396.6M
-9.73% -34.59%
-11.81
15.74
425.83% 18.94%
4.7B
-
-4.69% 71.46%
-7.23
60.35
54.84% -34.79%
3.3B
270.6M
-0.99% 6.40%
-13.71
12.12
440.80% -27.84%
3.1B
240.7M
-13.54% -18.95%
-10.32
12.72
-1.03% -92.09%
2.8B
726.4M
-12.42% -7.51%
-46.06
3.89
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-8.48% -15.36%
25.1
4.5
85.90% -14.05%
599.0M
983.7M
-18.48% -55.04%
-1.1
0.61
-50.36% 17.16%
428.3M
881.7K
-13.30% 407.71%
-9.6
466.16
-77.61% -5.33%
257.8M
4.9M
-1.96% -2.22%
-1.91
52.97
-54.97% 51.72%
7.2M
2.1M
77.59% 88.99%
-0.26
2.14
-13.45% 66.37%

Xenon Pharmaceuticals Inc News

Latest updates
Defense World11 Apr 202409:05 am
Zacks Investment Research2 months ago

Xenon Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32017Q42017Q32016Q42016Q32016Q22016Q12015Q4
Revenue-100.0%-132,000536,0008,766,0003,737,0008,124,0002,218,0004,358,0005,150,0006,554,00013,384,0007,078,0003,329,0003,500,00016,000264,000376,000413,000413,000601,0003,227,000
Operating Expenses13.3%43,331,00038,260,00030,851,00026,135,00028,575,00023,722,00024,716,00020,417,00018,073,00016,253,00014,030,00015,111,00014,927,00012,451,000-------
  S&GA Expenses-3.7%8,501,0008,829,0008,705,0006,775,0006,688,0004,831,0006,339,0004,109,0003,106,0003,208,0003,310,0003,320,0003,175,0002,700,000-------
  R&D Expenses18.3%34,830,00029,431,00022,146,00019,360,00021,887,00018,891,00018,377,00016,308,00014,967,00013,045,00010,720,00011,791,00011,752,0009,751,000-------
EBITDA Margin-53.2%-13.10-8.56-4.29-3.59-4.23-3.27-3.19-1.23-------------
Interest Expenses-----------154,000330,000348,000363,000-------
Income Taxes294.0%1,139,000-587,000-40,000-394,000484,000-205,000-217,000-68,000-14,000-203,000-39,000-1,000-36,0005,000-------
Earnings Before Taxes3.9%-36,256,000-37,737,000-31,198,000-20,064,000-25,080,000-15,650,000-22,326,000-15,832,000-12,337,000-9,058,000-214,000-7,485,000-11,412,000-8,866,000-------
EBT Margin-53.3%-13.28-8.66-4.35-3.64-4.28-3.33-3.26-1.27-------------
Net Income-0.7%-37,395,000-37,150,000-31,158,000-19,670,000-25,564,000-15,445,000-22,109,000-15,764,000-12,323,000-8,855,000-175,000-7,484,000-11,376,000-8,871,000-------
Net Income Margin-54.2%-13.29-8.62-4.34-3.62-4.28-3.31-3.23-1.26-------------
Free Cashflow-12.0%-34,484,000-30,788,000-17,412,000-18,640,000-21,224,000-15,230,000-13,986,000-21,112,000-------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets43.8%96567168572075477680755857226427529118919921123714899.00106115122
  Current Assets21.5%64553154553360064979554655925626728318219520723414596.00103112121
    Cash Equivalents49.3%14910065.0070.0057.0010337011717688.0083.0088.0045.0015.0044.0061.0025.0038.0037.0052.0068.00
  Net PPE-5.7%10.0010.0010.008.007.005.005.004.004.004.004.004.004.003.002.002.002.001.001.001.001.00
Liabilities6.9%37.0035.0038.0033.0033.0023.0022.0016.0022.0015.0018.0014.0018.0017.0021.0049.0056.0024.0023.0022.0019.00
  Current Liabilities10.2%27.0025.0028.0022.0023.0016.0014.008.0014.0013.0015.0011.0015.0017.0021.0049.0043.0012.009.006.004.00
  Long Term Debt-----------------11.0012.0013.0015.0015.00
    LT Debt, Current----------------16.005.004.002.00--
    LT Debt, Non Current-----------------11.0012.0013.0015.0015.00
Shareholder's Equity45.8%92863764668772175378654255024925727617118218918892.0075.0083.0092.00103
  Retained Earnings-7.2%-665-620-571-524-482-445-408-377-357-331-316-294-278-266-257-257-249-238-229-219-207
  Additional Paid-In Capital13.6%15713813914014213713312011770.0067.0065.0045.0044.0042.0041.0041.0040.0039.0039.0039.00
Shares Outstanding16.0%75.0065.0064.0063.0063.0059.0056.0055.0044.0040.0039.0037.00---------
Float---2,443---1,881---751---383---228--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations16.0%-35,465-42,230-33,221-34,411-32,732-30,402-16,868-18,428-20,710-15,007-13,077-20,708-13,114-11,154-10,789-13,06719,787-7,058-8,747-8,696-7,242
  Share Based Compensation5.0%9,1828,7438,4535,9945,8125,7425,2083,6142,7052,6432,7041,9651,6101,5801,4721,0151,357612464491575
Cashflow From Investing-599.1%-239,72648,03227,90246,622-14,335-234,0971,317-48,888-215,43315,5758,192-55,10443,199-18,03210,934-52,925-60,3187,740-6,628-7,003-12,556
Cashflow From Financing-324,014---6.00699269,8907,876323,9534,758111118,72145.00--16,720102,47027,43118.0011.0058.0034.00

XENE Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Revenue (note 11) $ 9,434$ 18,437
Operating expenses:   
Research and development$ 167,512105,76775,463
General and administrative46,54232,81021,967
Total operating expenses214,054138,57797,430
Loss from operations(214,054)(129,143)(78,993)
Other income (expense):   
Interest income27,6208,713466
Unrealized fair value gain (loss) on trading securities3,550(2,934)(719)
Foreign exchange gain (loss)199(1,891)358
Other income (expense)31,3693,888105
Loss before income taxes(182,685)(125,255)(78,888)
Income tax recovery (expense) (note 13)292(118)6
Net loss(182,393)(125,373)(78,882)
Net loss attributable to preferred shareholders (437)(1,795)
Net loss attributable to common shareholders(182,393)(124,936)(77,087)
Other comprehensive income (loss):   
Unrealized gain (loss) on available-for-sale securities (note 6)2,923(2,010) 
Comprehensive loss$ (179,470)$ (127,383)$ (78,882)
Net loss per common share (note 4):   
Basic$ (2.73)$ (2.06)$ (1.77)
Diluted$ (2.73)$ (2.06)$ (1.77)
Weighted-average common shares outstanding (note 4):   
Basic66,889,00560,542,14243,627,452
Diluted66,889,00560,542,14243,627,452

XENE Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 148,643$ 57,242
Marketable securities (note 6)489,439534,845
Accounts receivable874986
Prepaid expenses and other current assets6,0067,225
Total current assets644,962600,298
Marketable securities, long-term (note 6)292,792128,682
Operating lease right-of-use asset, net (note 8)9,19310,406
Property, plant and equipment, net (note 7)9,6536,500
Deferred tax assets (note 13)802509
Prepaid expenses, long-term7,3967,751
Total assets964,798754,146
Current liabilities:  
Accounts payable and accrued expenses (note 9)25,97422,214
Operating lease liability (note 8)1,299488
Total current liabilities27,27322,702
Operating lease liability, long-term (note 8)9,6049,947
Total liabilities36,87732,649
Shareholders’ equity:  
Common shares, without par value; unlimited shares authorized; issued and outstanding: 75,370,977 (December 31, 2022 - 62,587,701) (note 10)1,436,3741,065,136
Additional paid-in capital156,764142,108
Accumulated deficit(665,140)(482,747)
Accumulated other comprehensive loss(77)(3,000)
Total shareholders' equity927,921721,497
Total liabilities and shareholders’ equity964,798754,146
Commitments and contingencies (note 12)
XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
 CEO
 WEBSITExenon-pharma.com
 INDUSTRYBiotechnology
 EMPLOYEES203

Xenon Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Xenon Pharmaceuticals Inc? What does XENE stand for in stocks?

XENE is the stock ticker symbol of Xenon Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xenon Pharmaceuticals Inc (XENE)?

As of Fri Apr 12 2024, market cap of Xenon Pharmaceuticals Inc is 3.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XENE stock?

You can check XENE's fair value in chart for subscribers.

What is the fair value of XENE stock?

You can check XENE's fair value in chart for subscribers. The fair value of Xenon Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Xenon Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XENE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Xenon Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether XENE is over valued or under valued. Whether Xenon Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Xenon Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XENE.

What is Xenon Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, XENE's PE ratio (Price to Earnings) is -17.07 and Price to Sales (PS) ratio is 376.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XENE PE ratio will change depending on the future growth rate expectations of investors.